Merck to acquire Verona Pharma for $10 billion

Published 09/07/2025, 12:32
© Reuters

Investing.com -- Merck (NSE:PROR) said on Wednesday it has entered into a definitive agreement to acquire Verona Pharma PLC ADR (NASDAQ:VRNA) for $107 per American Depository Share, representing a total transaction value of approximately $10 billion.

The acquisition will add Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4, to Merck’s cardio-pulmonary pipeline and portfolio.

The FDA approved Ohtuvayre in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

Ohtuvayre is the first novel inhaled mechanism for COPD treatment in more than 20 years, combining bronchodilator and non-steroidal anti-inflammatory effects. The drug is also being evaluated for treating non-cystic fibrosis bronchiectasis.

Robert M. Davis, chairman and CEO of Merck, said the acquisition "reflects the commitment we have to delivering innovative treatments to patients and our ability to execute on our science-led and value-driven business development strategy."

David Zaccardelli, president and CEO of Verona Pharma, noted that since launching Ohtuvayre in August 2024, the company has seen "rapid and accelerating uptake in the U.S."

The transaction was unanimously approved by both companies’ boards of directors and is expected to close in the fourth quarter of 2025, subject to regulatory approvals and other customary conditions.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.